SWK Holdings Corporation (SWKH)
Market Cap | 229.23M |
Revenue (ttm) | 46.64M |
Net Income (ttm) | 16.99M |
Shares Out | 12.82M |
EPS (ttm) | 1.31 |
PE Ratio | 13.65 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,309 |
Open | 18.09 |
Previous Close | 17.80 |
Day's Range | 17.78 - 18.09 |
52-Week Range | 16.06 - 19.99 |
Beta | 0.33 |
Analysts | Buy |
Price Target | 26.01 (+45.47%) |
Earnings Date | May 8, 2023 |
About SWKH
SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately man... [Read more]
Financial Performance
In 2021, SWK Holdings's revenue was $56.16 million, an increase of 52.96% compared to the previous year's $36.71 million. Earnings were $25.93 million, an increase of 398.44%.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for SWKH stock is "Buy." The 12-month stock price forecast is $26.01, which is an increase of 45.47% from the latest price.
News

SWK Holdings Appoints Jerry Albright to Board of Directors
DALLAS , March 15, 2023 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-s...

SWK Holdings Provides Portfolio Update Highlighting Recent Achievements
Fourth Quarter and Full Year 2022 Financial Results to be Announced in March DALLAS , Jan. 31, 2023 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-foc...

SWK Holdings Names Jody Staggs Chief Executive Officer and Appoints Laurie Dotter as Chair of the Board
Mr. Staggs elevated from "interim" to "permanent" CEO as SWK advances multiple initiatives in 2023 Ms. Dotter joined SWK's Board of Directors in February 2022 DALLAS , Jan. 3, 2023 /PRNewswire/ -- SWK...

SWK Holdings Corporation Announces Upsizing of Credit Facility up to $50 Million
DALLAS , Nov. 16, 2022 /PRNewswire/ -- SW K Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-s...

SWK Holdings Corporation Announces Financial Results for Third Quarter 2022
Conference Call and Live Audio Webcast Scheduled for Thursday, November 10, 2022, at 10:00 a.m. ET Corporate Highlights Successful leadership transition with Jody Staggs named President and Interim Ch...

SWK Holdings Corporation to Report Third Quarter 2022 Financial Results
Conference Call and Live Audio Webcast Scheduled for Thursday, November 10, 2022, at 10:00 a.m. ET DALLAS , Nov. 8, 2022 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ: SWKH) ("SWK" or the "Company"...

Enteris BioPharma Presents Study of Ovarest® Demonstrating Oral Delivery Comparable to or Exceeding Injectable Leuprolide
Oral Presentation Delivered at the American Society for Reproductive Medicine Scientific (ASRM) 2022 Congress & Expo BOONTON, N.J. , Oct. 26, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnol...

SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics
Milestone payment highlights ongoing clinical progress of Oral KORSUVA™ DALLAS , Oct. 10 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance compan...

SWK Holdings Enhances Executive Management Team and Expands Underwriting Team
Yvette Heinrichson promoted to Chief Financial Officer John David Tamas promoted to Director of Underwriting DALLAS , Oct. 3, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the...

Enteris BioPharma Publishes White Paper Examining Factors to Consider While Evaluating Oral Administration of Peptides
Physicochemical properties of peptides can provide key insights to potential success of oral delivery BOONTON, N.J. , Sept. 12, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company de...

SWK Holdings to Participate in Lake Street Capital's 6th Annual Best Ideas Growth Conference "BIG6"
DALLAS , Sept. 7, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-st...

SWK Holdings Announces Leadership Transition
Jody Staggs appointed as President and Interim CEO CEO Winston Black will assist in an interim consulting role after successfully establishing SWK Holdings as a leading life science focused specialty ...

SWK Holdings Corporation Announces Financial Results for Second Quarter 2022
Conference Call and Live Audio Webcast Scheduled for Thursday, August 11, 2022, at 10:00 a.m. ET Corporate Highlights Celebrated 10th anniversary as a life science focused specialty finance company ca...

SWK Holdings Corporation to Report Second Quarter 2022 Financial Results
Conference Call and Live Audio Webcast Scheduled for Thursday, August 11, 2022, at 10:00 a.m. ET DALLAS , Aug. 9, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"),...

Enteris BioPharma Manufacturing Expertise Highlighted in Drug Development & Delivery Special Feature on Outsourcing Formulation Development & Manufacturing
Article describes Enteris' strengths and scalability in working with highly potent active pharmaceutical ingredients BOONTON, N.J. , August 3, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechno...

Enteris BioPharma Announces Acceptance of Abstract for Oral Presentation at ASRM 2022 Scientific Congress & Expo
BOONTON, N.J. , July 14, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned su...

SWK Holdings Corporation Marks 10th Anniversary, Celebrating Growth and Progress
Since 2012, SWK Holdings has completed financings with 46 life sciences companies, deploying $650 million of capital Second Quarter 2022 Financial Results to be Announced in August DALLAS , July 13, 2...

SWK Holdings Corporation Added to Russell 3000® Index, Russell 2000® Index and Russell Microcap® Index
DALLAS , June 27, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life science-focused specialty finance company catering to small-and mid-sized commercial-stage companies, announced t...

Enteris BioPharma Presents Data from Two Clinical Studies Involving Oral Formulations of Leuprolide at ENDO 2022 Annual Conference
Data suggest that oral formulations of leuprolide developed utilizing Enteris' Peptelligence® platform successfully deliver meaningful circulating drug concentrations and achieve hormonal suppressive ...

Enteris BioPharma Publishes White Paper Examining Safe Handling and Manufacture of Highly Potent Active Pharmaceutical Ingredients (HPAPI)
Facilities and processes key to protecting workers and the environment, the paper in Drug Development & Delivery says BOONTON, N.J. , June 7, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnol...

Enteris Employees Lend Ronald McDonald House a Helping Hand at Enteris Day 2022
BOONTON, N.J. , May 26, 2022 /PRNewswire/ -- Enteris BioPharma, Inc. gave plush animals a dose of personality as they created a dozen stuffed teddy bears for Ronald McDonald House Charities to help c...

SWK Holdings Corporation Announces Filing of Form S-3 Shelf Registration Statement
Authorizes 10b5-1 Stock Repurchase Program DALLAS , May 19, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company cate...

SWK Holdings Corporation Announces Financial Results for First Quarter 2022
Conference Call and Live Audio Webcast Scheduled for Wednesday, May 11, 2022, at 10:00 a.m. ET Corporate Highlights During first quarter of 2022, completed two structured debt transactions deploying $...

SWK Holdings Corporation to Report First Quarter 2022 Financial Results
Conference Call and Live Audio Webcast Scheduled for Wednesday, May 11, 2022, at 10:00 a.m. ET DALLAS , May 10, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a...

Enteris BioPharma to Exhibit at CPhI North America 2022
BOONTON, N.J. , May 4, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subs...